久久婷婷国产综合精品,久久久久久久性潮,换脸国产av一区二区三区,韩国精品一区二区三区无码视频 ,久久久久成人精品无码

  • Overview of New "Don't Eat Me" Target CD24 Research Zhaoruijie/PharmaSources
    July 03, 2023
    Recently, Antengene Corporation announced that the Phase I clinical trial application (IND) of its global first anti-CD24 monoclonal antibody, ATG-031, had been approved by FDA.
PharmaSources Customer Service